[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577106":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"LifeBridge Health","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Autologous Platelet Rich Plasma","EXPERIMENTAL","\\~Injection of approximately 10 mL autologous PRP Magellan Autologous Concentration System, ISTO Biologics",[13],"Device: Platelet Rich Plasma Joint Injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Corticosteroid","ACTIVE_COMPARATOR","5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)",[19],"Drug: Corticosteroid Injection",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Platelet Rich Plasma Joint Injection","Magellan Autologous Concentration System, ISTO Biologics",[9],null,{"type":28,"name":29,"description":17,"armGroupLabels":30,"otherNames":26},"DRUG","Corticosteroid Injection",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Martin Gesheff, DHSc","CONTACT","410-601-9467","mgesheff@lifebridgehealth.org",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Sinai Hospital of Baltimore","RECRUITING","Baltimore","Maryland","21215","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-76.61219,39.29038,{"lat":50,"lon":49},[53,54],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":55,"role":56,"phone":26,"phoneExt":26,"email":26},"Michael A Mont, MD","PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[60],{"name":61,"class":62},"Hip Society","UNKNOWN","100577106","phase-4-platelet-rich-plasma-versus-corticosteroids-in-hip-osteoarthritis-pain-100577106",false,"NCT06793982","Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain","The Efficacy of Platelet Rich Plasma Compared With Corticosteroid Injections for the Treatment of Pain Associated With Hip Osteoarthritis","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 21-80 years\n* Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis\n* Indicated for a Hip injection to treat Hip OA symptoms\n\nExclusion Criteria:\n\n* Any injections into the target Hip within three months\n* Current overlying skin infection\n* Current or previous diagnosis of \"chronic pain\"\n* Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)\n* Allergy to any potential ingredients or medications utilized in any of the two groups\n* Treatment with another investigational drug or other intervention for pain\n* Diagnosis of Diabetes Mellitus\n* If female, pregnant or planning to be pregnant within the following 3 months or study duration\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation","ALL","21 Years","80 Years",{"count":74,"type":75},54,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.",[81],"Hip Osteoarthritis",[83,84,85,86,87],"platelet rich plasma","hip osteoarthritis","PRP","hip OA","Corticosteroids","2025-03-11",{"date":90,"type":91},"2025-03-14","ACTUAL",{"date":93,"type":91},"2024-02-21",{"date":95,"type":75},"2025-12-01",{"name":5,"class":6},1]